Clinical Trial Update: Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy [Phase 3]

View source ↗

Summary

Phase III trial evaluating canakinumab with docetaxel in adults with non-small cell lung cancer as second or third-line therapy; study terminated with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Canakinumab (canakinumab)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Small-Cell Lung | Phase 3 | Status: TERMINATED | Results posted: 2023-06-22